Indiana University School of Medicine, Indianapolis, IN, USA,
Qual Life Res. 2014 Feb;23(1):75-88. doi: 10.1007/s11136-013-0436-3. Epub 2013 May 26.
The purpose of this study is to assess if diagnosis of type 2 diabetes affected health-related quality of life (HRQoL) among participants in the Diabetes Prevention Program/Diabetes Prevention Program Outcome Study and changes with treatment or diabetes duration.
3,210 participants with pre-diabetes were randomized to metformin (MET), intensive lifestyle intervention (ILS), or placebo (PLB). HRQoL was assessed using the SF-36 including: (1) 8 SF-36 subscales; (2) the physical component (PCS) and mental component summary (MCS) scores; and (3) the SF-6D. The sample was categorized by diabetes free versus diagnosed. For diagnosed subgroup, mean scores in the diabetes-free period, at 6 months, 2, 4 and 6 years post-diagnosis, were compared.
PCS and SF-6D scores declined in all participants in all treatment arms (P < .001). MCS scores did not change significantly in any treatment arm regardless of diagnosis. ILS participants reported a greater decrease in PCS scores at 6 months post-diagnosis (P < .001) and a more rapid decline immediately post-diagnosis in SF-6D scores (P = .003) than the MET or PLB arms. ILS participants reported a significant decrease in the social functioning subscale at 6 months (P < .001) and two years (P < .001) post-diagnosis.
Participants reported a decline in measures of overall health state (SF-6D) and overall physical HRQoL, whether or not they were diagnosed with diabetes during the study. There was no change in overall mental HRQoL. Participants in the ILS arm with diabetes reported a more significant decline in some HRQoL measures than those in the MET and PLB arms that developed diabetes.
本研究旨在评估 2 型糖尿病诊断是否会影响糖尿病预防计划/糖尿病预防计划结局研究参与者的健康相关生活质量(HRQoL),以及治疗或糖尿病病程的变化是否会影响 HRQoL。
3210 名患有前驱糖尿病的参与者被随机分配到二甲双胍(MET)、强化生活方式干预(ILS)或安慰剂(PLB)组。使用 SF-36 评估 HRQoL,包括:(1)8 个 SF-36 子量表;(2)生理成分(PCS)和心理成分综合评分(MCS);和(3)SF-6D。该样本按无糖尿病与诊断为糖尿病进行分类。对于诊断亚组,比较无糖尿病期、诊断后 6 个月、2、4 和 6 年的平均得分。
所有治疗组的参与者的 PCS 和 SF-6D 评分均下降(P<0.001)。无论是否诊断为糖尿病,任何治疗组的 MCS 评分均无显著变化。ILS 组参与者在诊断后 6 个月时 PCS 评分下降更明显(P<0.001),SF-6D 评分在诊断后即刻下降更快(P=0.003),而 MET 或 PLB 组则不然。ILS 组参与者在诊断后 6 个月(P<0.001)和两年(P<0.001)时社会功能子量表显著下降。
无论参与者在研究期间是否被诊断为糖尿病,他们都报告了总体健康状况(SF-6D)和总体身体 HRQoL 下降。整体心理健康 HRQoL 没有变化。患有糖尿病的 ILS 组参与者报告的某些 HRQoL 指标下降幅度大于 MET 和 PLB 组参与者,后者也发展为糖尿病。